AtaiBeckley Logs $660M 2025 Loss, Eyes Q2 2026 Phase 3 BPL-003 Launch
AtaiBeckley ended 2025 with $220.7M in cash and equivalents but posted a $660M net loss including a $530M non-cash acquisition charge. Its BPL-003 nasal spray Phase 3 pivotal program, comprising two FDA-backed studies, will launch in Q2 2026 with topline results due by early 2029.
1. 2025 Financial Results
AtaiBeckley reported a net loss of $660 million for 2025, which included a $530 million non-cash charge tied to the Beckley Psytech acquisition. The company ended the year with $220.7 million in cash, cash equivalents, and short-term securities.
2. BPL-003 Phase 3 Program
The BPL-003 nasal spray for treatment-resistant depression will enter a pivotal Phase 3 program in Q2 2026, featuring two FDA-backed studies named ReConnection-1 and ReConnection-2. Topline data from these trials is expected by early 2029, marking a key milestone for the therapy.
3. Pipeline Progress and Patents
Additional pipeline candidates advanced as VLS-01 buccal film is set to report Phase 2 topline data in H2 2026, while EMP-01 met primary safety objectives in an exploratory Phase 2a social anxiety trial and demonstrated meaningful efficacy improvements. A new US patent for EMP-01 extends its exclusivity through 2043.
4. Liquidity Outlook
With $220.7 million in liquidity at year-end, management projects funding for operations into early 2029, covering the anticipated timeline for major Phase 3 readouts. This cash runway aligns with the company’s strategic focus on late-stage clinical development.